NXTS vs MRNA vs INSM Stock Comparison

Nexentis Technologies, Moderna and Insmed Prices as of Nov 13, 2026 Peers: Industry group
MRNA Moderna, Inc.
$223.37 -1.3% 1M +794.9% 1Y
Market cap
$86.12B
P/E
–
Revenue (TTM)
$2.53B
Div. yield
–
Biotechnology Healthcare
3 wins
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$26.90B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
5 wins

Head to Head

9 decided of 12

Insmed leads on 5 of the 12 questions below (Insmed 5, Moderna 3, Nexentis Technologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSMRNAINSMLeader
Larger companyMarket capitalisation $330.53K $86.12B $26.90B MRNA
Cheaper on earningsLower P/E, profitable companies only 0.0x -30.9x -44.4x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — — –
Faster revenue growthRevenue growth, trailing twelve months -4,237.5% +13.1% +240.0% INSM
More profitableNet margin, trailing twelve months — -110.5% -39.9% INSM
Better return on capitalReturn on invested capital — -39.6% -41.1% MRNA
Less leveragedLower net debt / EBITDA 0.8x 1.7x 1.1x NXTS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -90.3% +794.9% -36.6% MRNA
Better 5-year returnAnnualised price return, 5 years -82.4%/yr -0.7%/yr +30.6%/yr INSM
Less volatileAnnualised volatility, 1 year 235.4% 130.6% 62.2% INSM
Higher overall scoreMean of the five percentile scores vs peers 18/100 60/100 66/100 INSM

Percentile Scorecard

NXTSMRNAINSM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSMRNAINSM
Valuation 7 #612 of 660 69 #208 of 660 70 #201 of 660
Growth 6 #585 of 619 45 #344 of 619 85 #91 of 619
Profitability 22 #462 of 595 60 #239 of 595 69 #186 of 595
Financial Health 38 #423 of 683 52 #330 of 683 37 #428 of 683
Shareholder Returns – 76 #112 of 459 67 #153 of 459
Overall 18 60 66
  • NXTS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • MRNA ranked among 695 companies in Pharmaceuticals and Biotechnology
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSMRNAINSMSPY
1 month +229.2%-1.3%+23.9% -2.0%
3 months +12.0%+252.8%-2.1% -2.8%
6 months -52.0%+355.5%+11.0% +2.0%
Year to date -81.8%+657.4%-30.4% +10.6%
1 year -90.3%+794.9%-36.6% +12.2%
3 years -99.6%+201.4%+393.7% +68.1%
3 years, per year -84.2%+44.5%+70.3% +18.9%
5 years -100.0%-3.4%+280.3% +61.4%
5 years, per year -82.4%-0.7%+30.6% +10.1%
10 years -100.0%—+738.5% +248.5%
10 years, per year -61.8%—+23.7% +13.3%

Risk

MeasureNXTSMRNAINSMSPY
Volatility, 1Y 235.4%130.6%62.2% 13.6%
Downside volatility, 1Y 158.4%79.2%61.0% 13.9%
Beta vs S&P 500, 1Y 4.332.260.55 1.00
Return / volatility, 1Y -0.386.09-0.59 0.90
Max drawdown, 5Y -100.0%-93.9%-56.5% -25.4%
From 52-week high -90.5%-16.9%-42.7% -3.2%
52-week high $22.54$268.86$211.41 $779.14
52-week low $0.48$22.36$91.88 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSMRNAINSM
P/E now vs peer median 0.0xmedian 17.0x -32.1xmedian 17.0x -43.8xmedian 17.0x
P/S now vs peer median 0.0xmedian 8.4x 35.7xmedian 8.4x 17.5xmedian 8.4x
EV/EBITDA now vs peer median 0.8xmedian 14.6x -32.0xmedian 14.6x -48.6xmedian 14.6x
P/FCF now vs peer median -0.1xmedian 19.0x -45.8xmedian 19.0x -42.3xmedian 19.0x
P/B now vs peer median 0.2xmedian 2.0x 13.2xmedian 2.0x 36.6xmedian 2.0x
PEG now vs peer median 0.00median 0.43 -3.01median 0.43 -2.40median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSMRNAINSM
Revenue -$8.94M $2.53B $1.52B
Gross profit – $707.00M $1.28B
Operating income -$10.88M -$2.93B -$563.99M
Net income -$16.14M -$2.79B -$605.67M
Free cash flow -$4.50M -$1.97B -$627.58M
R&D $798.00K $2.66B $944.39M
EPS (diluted) $-98.21 $-6.49 $-2.77
Cash & equivalents $7.62M $1.20B $396.60M
Total debt $422.00K $591.00M $555.09M
Shares (diluted) 163.23K 430.00M 218.79M
Enterprise value -$25.11M $64.81B $21.94B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSMRNAINSM
P/E 0.0x -32.1x -43.8x
P/FCF -0.1x -45.8x -42.3x
P/Operating cash flow -0.1x -50.6x -44.6x
P/S 0.0x 35.7x 17.5x
P/B 0.2x 13.2x 36.6x
P/Tangible book -0.2x 13.2x 45.2x
EV/EBITDA 0.8x -32.0x -48.6x
EV/EBIT 0.7x -29.2x -46.1x
EV/Revenue 0.9x 33.9x 17.1x
EV/FCF 1.8x -43.5x -41.4x
EV/Operating cash flow 1.8x -48.0x -43.6x
PEG (3Y EPS CAGR) 0.00 -3.01 -2.40

Growth

14 metrics
MetricNXTSMRNAINSM
Revenue growth (1Y) -4,238% 13.1% 240.0%
Revenue CAGR (3Y) -182.9% -34.8% 75.6%
Gross profit growth (1Y) – -34.4% 274.9%
Gross profit CAGR (3Y) – -41.0% 79.8%
Operating income growth (1Y) -127.3% 15.4% 51.3%
Operating income CAGR (3Y) -23.5% -3.2% 6.2%
Net income growth (1Y) -70.1% 10.5% 48.8%
Net income CAGR (3Y) -42.2% 7.0% 5.8%
EPS growth (1Y) -666.2% 18.8% 50.5%
EPS CAGR (3Y) -52.0% 10.7% 18.2%
Operating cash flow growth (1Y) -62.8% 9.8% 32.6%
Operating cash flow CAGR (3Y) -0.4% 4.9% -5.4%
Free cash flow growth (1Y) -65.5% 25.7% 30.7%
Free cash flow CAGR (3Y) -0.7% 9.5% -6.2%

Profitability

14 metrics
MetricNXTSMRNAINSM
Gross margin – 28.0% 84.4%
EBITDA margin – -105.9% -35.1%
Operating margin – -116.0% -37.1%
Pretax margin – -108.1% -39.4%
Net margin – -110.5% -39.9%
FCF margin – -78.0% -41.3%
Operating cash flow margin 49.6% -70.7% -39.2%
Return on equity -218.6% -41.0% -81.9%
Return on assets -92.0% -22.8% -28.1%
Return on invested capital – -39.6% -41.1%
Return on capital employed -73.7% -28.8% -36.0%
Asset turnover -0.5x 0.2x 0.7x
Cash conversion (OCF / net income) 0.3x 0.6x 1.0x
Stock comp / revenue -11.0% 18.4% 11.0%

Financial Health

11 metrics
MetricNXTSMRNAINSM
Debt / assets 2.3% 4.4% 24.9%
Debt / equity 0.2x 0.1x 0.8x
Net debt / EBITDA 0.8x 1.7x 1.1x
Debt / FCF -0.1x -0.3x -0.9x
Liabilities / assets 89.8% 49.2% 67.4%
Equity / assets 10.2% 50.8% 32.6%
Interest coverage – – -5.5x
Current ratio 3.7x 3.6x 2.9x
Quick ratio 3.2x 3.2x 2.4x
Cash ratio 3.2x 2.5x 1.9x
Altman Z-score -6.11 8.66 7.36

Shareholder Returns

7 metrics
MetricNXTSMRNAINSM
Dividend yield – – –
Net buyback yield -2,794% -0.2% -0.4%
Shareholder yield -2,794% -0.2% -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSMRNAINSM
EPS, next fiscal year – $-7.17FY2026 $-1.68FY2026
Revenue, next fiscal year – $2.22BFY2026 $1.99BFY2026
Revenue growth, next FY – +14.6%FY2026 +227.7%FY2026
Revenue growth, the year after – +25.8% +59.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSMRNAINSM
Held by institutions – 80.2% 100.0%
Institutions holding – 787 671
Change in shares held, QoQ – +3.4% +3.4%
Institutions buying – 404 369
Institutions selling – 239 230
Buyers to sellers – 1.69 1.60

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSMRNAINSM
NXTS 1.00 0.00 0.00
MRNA 0.00 1.00 0.10
INSM 0.00 0.10 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS, MRNA and INSM?

Moderna (MRNA) is the largest by market capitalisation: Nexentis Technologies (NXTS) $330.53K, Moderna (MRNA) $86.12B, Insmed (INSM) $26.90B.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Nexentis Technologies (NXTS) -4,237.5%, Moderna (MRNA) +13.1%, Insmed (INSM) +240.0%.

Which company is more profitable?

Insmed (INSM) has the highest net margin (Moderna (MRNA) -110.5%, Insmed (INSM) -39.9%). On return on invested capital, Moderna (MRNA) leads (Moderna (MRNA) -39.6%, Insmed (INSM) -41.1%).

Which stock has performed better?

Over the past year Moderna (MRNA) returned the most: Nexentis Technologies (NXTS) -90.3%, Moderna (MRNA) +794.9%, Insmed (INSM) -36.6%. Over five years, Insmed (INSM) compounded fastest (Nexentis Technologies (NXTS) -82.4%/yr, Moderna (MRNA) -0.7%/yr, Insmed (INSM) +30.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Insmed (INSM) has been the steadiest (Nexentis Technologies (NXTS) 235.4%, Moderna (MRNA) 130.6%, Insmed (INSM) 62.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NXTS, MRNA and INSM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Insmed (INSM) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.